Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering Biosensors to Enhance Monoterpene Indole Alkaloid Production in Yeast.

bioRxiv : the preprint server for biology·2026
Same author

Ligify 2.0: a web server for predicted small molecule biosensors.

Nucleic acids research·2026
Same author

groovDB in 2026: a community-editable database of small molecule biosensors.

Nucleic acids research·2025
Same author

Rational design of selective bispecific EPO-R/CD131 agonists.

bioRxiv : the preprint server for biology·2025
Same author

A coronaviral pore-replicase complex links RNA synthesis and export from double-membrane vesicles.

Science advances·2024
Same author

Ten Years of the Synthetic Biology Summer Course at Cold Spring Harbor Laboratory.

ACS synthetic biology·2024
Same journal

Combining bacterial display and protein language models to engineer a CD69-binding affibody for molecular imaging of immune activation.

Protein engineering, design & selection : PEDS·2026
Same journal

Examining selection dynamics and limitations in multi-round protein selection of high diversity libraries.

Protein engineering, design & selection : PEDS·2026
Same journal

A photo-enhanced oxidative coupling for site-specific protein Labeling via noncanonical amino acid incorporation.

Protein engineering, design & selection : PEDS·2026
Same journal

Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.

Protein engineering, design & selection : PEDS·2026
Same journal

Integrating machine learning tools in protein design: a case of MHETase engineering for PET biodeconstruction.

Protein engineering, design & selection : PEDS·2026
Same journal

Computational redesign of a thermostable T7 RNA polymerase.

Protein engineering, design & selection : PEDS·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.1K

Rational design of selective bispecific EPO-R/CD131 agonists.

Kailyn E Doiron1,2,3, Jeffrey C Way1,2, Pamela A Silver1,2

  • 1Department of Systems Biology, Harvard Medical School, 210 Longwood Avenue, Boston, MA 02115, USA.

Protein Engineering, Design & Selection : PEDS
|November 9, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed novel bispecific proteins to activate EPO-R/CD131 signaling, offering a new approach for cytokine receptor agonist development and understanding EPO-R/CD131 biology.

Keywords:
CytokineErythropoietinNeuroprotectionSTAT5scFv

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.6K

Related Experiment Videos

Last Updated: Jun 7, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.1K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.6K

Area of Science:

  • Biochemistry and Molecular Biology
  • Immunology
  • Structural Biology

Background:

  • Erythropoietin (EPO) signaling is crucial for cell survival, acting via EPO-R/EPO-R or EPO-R/CD131 complexes.
  • The precise mechanism and structural basis of EPO signaling through EPO-R/CD131 remain incompletely understood and debated.

Purpose of the Study:

  • To construct a structural model of the EPO-R/CD131 complex.
  • To design and validate bispecific proteins that selectively activate EPO-R/CD131 signaling.

Main Methods:

  • Structural modeling of the EPO-R/CD131 complex.
  • Design and engineering of anti-EPO-R and anti-CD131 bispecific proteins (tandem scFv, bispecific antibody formats).
  • Assessment of STAT5 phosphorylation as a readout for EPO-R/CD131 activation.

Main Results:

  • A structural model of EPO-R/CD131 was developed.
  • Engineered bispecific proteins, particularly in tandem scFv and bispecific antibody formats, selectively activated EPO-R/CD131.
  • Activation was confirmed by STAT5 phosphorylation, independent of EPO-R/EPO-R engagement.
  • Modifications to binding domain arrangement and linker length aligned with the structural model.

Conclusions:

  • Bispecific scaffolds are effective tools for developing cytokine receptor agonists.
  • The study provides a foundation for further investigation into EPO-R/CD131 biology.
  • These findings support the potential for future clinical development of EPO-R/CD131-targeting therapeutics.